Orthopedics

Osteoarthritis is the most common degenerative joint disease, affecting more than 500 million people worldwide. Mesenchymal stem cells (MSC) represent a promising therapeutic approach for treating osteoarthritis and other orthopedic conditions due to their potent anti-inflammatory and regenerative properties.

Clinical studies have shown that intra-articular application of MSC cells reduces pain, improves joint function, and slows the progression of cartilage degeneration. MSC cells work by secreting bioactive molecules that promote cartilage repair, reduce inflammation, and modulate the immune response in the joint.

GaiaCell offers GMP-certified MSC therapies for treating osteoarthritis of large and small joints, meniscal injuries, tendinopathies, and bone defects. Our approach is based on the latest clinical evidence and personalized treatment for each patient.